Search

Your search keyword '"Richardson, Paul G."' showing total 97 results

Search Constraints

Start Over You searched for: Author "Richardson, Paul G." Remove constraint Author: "Richardson, Paul G." Database Journals@OVID Remove constraint Database: Journals@OVID
97 results on '"Richardson, Paul G."'

Search Results

1. Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes

2. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

5. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial

7. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis

9. Supplement to: Targeting CD38 with daratumumab monotherapy in multiple myeloma.

10. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

13. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

16. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations

19. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide

27. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

28. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib

36. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

42. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

49. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

Catalog

Books, media, physical & digital resources